Glutamate receptors: the cause or cure in perinatal white matter injury?

Area of Science:

• Neuroscience
• Developmental Neuroscience
• Neuroprotection

Background:

• Perinatal hypoxia-ischaemia causes glutamate excitotoxicity, leading to white matter injury and long-term neurological deficits.
• Previous attempts to block ionotropic glutamate receptors (GluRs) have failed in clinical trials for preventing such injuries.
• Developing oligodendrocytes transiently express group I metabotropic glutamate receptors (mGluRs) during the perinatal period.

Purpose of the Study:

• To investigate the therapeutic potential of activating group I mGluRs on developing oligodendrocytes.
• To evaluate the efficacy of a blood-brain-barrier permeable group I mGluR agonist in a preclinical model of white matter injury.

Main Methods:

• Utilized a rat model of perinatal hypoxia-ischaemia to induce white matter damage.
• Administered 1-aminocyclopentane-trans-1,3-dicarboxylic acid (ACPD), a group I mGluR agonist, to assess its neuroprotective effects.
• Quantified white matter damage and neurological outcomes in treated and control groups.

Main Results:

• ACPD administration significantly reduced white matter damage in the rat model.
• Activation of group I mGluRs demonstrated a neuroprotective effect on developing oligodendrocytes.
• The findings suggest a promising therapeutic strategy for mitigating hypoxic-ischaemic brain injury.

Conclusions:

• Targeting group I mGluRs represents a novel therapeutic avenue for preventing diffuse white matter injury in premature infants.
• This approach holds potential for preventing neurological impairments such as cerebral palsy.
• Further research into mGluR agonists could lead to new treatments for neonatal brain injury.